Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00336063 · ClinicalTrials.gov registry record · Phase 1
Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
A Phase 1 study of Adult Nasal Type Extranodal NK/T-cell Lymphoma and Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 5
- Study locations
NCT00336063 is a Phase 1 study of Adult Nasal Type Extranodal NK/T-cell Lymphoma and Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 18 participants, below the 39-participant average among 13 other Adult Nasal Type Extranodal NK/T-cell Lymphoma trials with a reported enrollment target (54% lower). The trial reports 5 study locations across 2 states.
The verdict
NCT00336063, a Phase 1 study of Adult Nasal Type Extranodal NK/T-cell Lymphoma and Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of vorinostat when given together with azacitidine in treating patients with nasopharyngeal cancer or nasal natural killer T-cell lymphoma that has recurred (come back) at or near the same place as the original (primary) tumor, usually after a period of time during which the cancer could not be detected or has spread to other parts of the body. Drugs used in chemotherapy, such as vorinostat and azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vorinostat and azacitidine also may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with azacitidine may kill more cancer cells.
Conditions Studied
Interventions
- DRUG Azacitidine
- OTHER Laboratory Biomarker Analysis
- DRUG Vorinostat
- OTHER Pharmacological Study
Study Locations (5)
Other
- Chinese University of Hong Kong-Prince of Wales Hospital - Shatin
- National Cancer Center Hospital - Tokyo
- National University Hospital Singapore - Singapore
- National Cancer Centre Singapore - Singapore
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-03-03 |
| Est. Completion | 2026-03-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00336063
The ClinicalTrials.gov registry entry for NCT00336063 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 39-participant average among 13 other Adult Nasal Type Extranodal NK/T-cell Lymphoma trials with a reported enrollment target (54% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Adult Nasal Type Extranodal NK/T-cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Azacitidine is the first listed.
NCT00336063 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Other, Maryland.
Frequently Asked Questions
What is clinical trial NCT00336063 about?
NCT00336063 is a clinical study titled "Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma". This phase I trial studies the side effects and best dose of vorinostat when given together with azacitidine in treating patients with nasopharyngeal cancer or nasal natural killer T-cell lymphoma that has recurred (come back) at or near the same place as the original (primary) tumor, usually after ...
What is the current status of trial NCT00336063?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2006-03-03. Estimated completion is 2026-03-19.
What conditions does trial NCT00336063 study?
This clinical trial studies the following conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Nasopharyngeal Undifferentiated Carcinoma.
What interventions are being tested in trial NCT00336063?
The interventions under investigation include: Azacitidine (DRUG), Laboratory Biomarker Analysis (OTHER), Vorinostat (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT00336063?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00336063 being conducted?
This trial has 5 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Nasal Type Extranodal NK/T-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
COMPLETED · Phase 1
-
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
COMPLETED · Phase 1
-
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
COMPLETED · Phase 1
-
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
COMPLETED · Phase 1
-
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
COMPLETED · Phase 1
-
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
COMPLETED · Phase 1
Explore more on PlainTrial
Adult Nasal Type Extranodal NK/T-cell Lymphoma
All registered trials for this condition
Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.